Last reviewed · How we verify
Adapalen — Competitive Intelligence Brief
marketed
Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Adapalen (Adapalen) — Technische Universität Dresden.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adapalen TARGET | Adapalen | Technische Universität Dresden | marketed | Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha | ||
| differin | differin | University of Magdeburg | marketed | Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Adapalen — Competitive Intelligence Brief. https://druglandscape.com/ci/adapalen. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab